Assessing temporal agreement between central and local progression-free survival times.

@article{Zeng2015AssessingTA,
  title={Assessing temporal agreement between central and local progression-free survival times.},
  author={Donglin Zeng and Emil Cornea and Jun Dong and Jean Pan and Joseph G. Ibrahim},
  journal={Statistics in medicine},
  year={2015},
  volume={34 5},
  pages={844-58}
}
In oncology clinical trials, progression-free survival (PFS), generally defined as the time from randomization until disease progression or death, has been a key endpoint to support licensing approval. In the U.S. Food and Drug Administration guidance for industry, May 2007, concerning the PFS as the primary or co-primary clinical trial endpoint, it is recommended to have tumor assessments verified by an independent review committee blinded to study treatments, especially in open-label studies… CONTINUE READING